PMID: 8610104Apr 2, 1996Paper

Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins

Proceedings of the National Academy of Sciences of the United States of America
J C BeckerRalph A Reisfeld

Abstract

Antibody-cytokine fusion proteins combine the unique targeting ability of antibodies with the multifunctional activity of cytokines. Here, we demonstrate the therapeutic efficacy of such constructs for the treatment of hepatic and pulmonary metastases of different melanoma cell lines. Two antibody-interleukin 2 (IL-2) fusion proteins, ch225-IL2 and ch14.18-IL2, constructed by fusion of a synthetic sequence coding for human IL-2 to the carboxyl end of the Cgamma1 gene of the corresponding antibodies, were tested for their therapeutic efficacy against xenografted human melanoma in vivo. Tumor-specific fusion proteins completely inhibited the growth of hepatic and pulmonary metastases in C.B-17 scid/scid mice previously reconstituted with human lymphokine-activated killer cells, whereas treatment with combinations of the corresponding antibodies plus recombinant IL-2 only reduced the tumor load. Even when treatment with fusion proteins was delayed up to 8 days after inoculation of tumor cells, it still resulted in complete eradication of micrometastases that were established at that time point. Selection of tumor cell lines expressing or lacking the targeted antigen of the administered fusion protein proved the specificity of the ...Continue Reading

References

Feb 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·S D GilliesR A Reisfeld
Jul 18, 1991·The New England Journal of Medicine·H K Koh
Aug 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·B M MuellerS D Gillies
Dec 20, 1989·Journal of Immunological Methods·S D GilliesJ Wesolowski
Jun 1, 1995·Immunology Today·D M GoldenbergJ Schlom
Apr 1, 1995·European Journal of Immunology·G Schmidt-Wolf, I G Schmidt-Wolf
Oct 1, 1994·Current Opinion in Immunology·M A Ghetie, E S Vitetta
Oct 1, 1994·Current Opinion in Immunology·J G Jurcic, D A Scheinberg
Dec 1, 1994·Immunology Today·A J GeorgeA A Epenetos
Sep 27, 1994·Proceedings of the National Academy of Sciences of the United States of America·H SabzevariR A Reisfeld
Dec 1, 1994·The New England Journal of Medicine·S P Naber
Jan 1, 1994·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·J A HankM Bauer
Jan 1, 1993·Cancer Immunology, Immunotherapy : CII·R A MaasW Den Otter
May 14, 1993·Science·A Lanzavecchia

❮ Previous
Next ❯

Citations

Jul 28, 2011·Cancer Immunology, Immunotherapy : CII·Jennifer A A GubbelsJoseph Connor
Dec 21, 2000·Current Oncology Reports·N K Cheung
Jun 6, 2000·Advanced Drug Delivery Reviews·L Zardi, D Neri
Jun 29, 2001·Trends in Immunology·R B BankertS D Hess
Jan 21, 2006·Nature Reviews. Drug Discovery·David SchramaJürgen C Becker
Jul 23, 1996·Proceedings of the National Academy of Sciences of the United States of America·J C BeckerR A Reisfeld
Jan 14, 2000·Journal of Hematotherapy & Stem Cell Research·L ZhaoH P Fell
Mar 6, 2004·Hybridoma and Hybridomics·Jiali LiAlan L Epstein
Sep 3, 1998·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·M L PenichetS L Morrison
Nov 15, 1997·Journal of the National Cancer Institute·H N LodeR A Reisfeld
Aug 7, 1999·APMIS. Supplementum·H J Ditzel
Jun 7, 2000·The Journal of Clinical Investigation·H N LodeR A Reisfeld
Oct 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David M KingPaul Sondel
Apr 4, 2014·Cancer Immunology, Immunotherapy : CII·Karīna SiliņaAija Linē
Jul 21, 1999·Proceedings of the National Academy of Sciences of the United States of America·H N LodeR A Reisfeld
Jul 22, 1997·Proceedings of the National Academy of Sciences of the United States of America·H J DitzelJ C Jensenius
Jul 22, 1998·Proceedings of the National Academy of Sciences of the United States of America·P T StratenJ C Becker
Jul 3, 2007·Cancer Immunology, Immunotherapy : CII·David SchramaJürgen C Becker
Dec 30, 2003·International Journal of Cancer. Journal International Du Cancer·Peter RufHorst Lindhofer
Feb 1, 2012·Drug Discovery Today·Nadine Pasche, Dario Neri
Nov 8, 2015·The Lancet Oncology·Yanni ZhuKhalid Shah
Jan 5, 2002·Hematology/oncology Clinics of North America·N K CheungK Kramer
May 15, 2003·The Surgical Clinics of North America·Alan S Kadison, Donald L Morton
Jul 25, 2013·Journal of Biomolecular Structure & Dynamics·Lucas Joel GutiérrezHéctor Armando Baldoni
May 27, 2010·British Journal of Cancer·P WorkmanUNKNOWN Committee of the National Cancer Research Institute
Dec 24, 1997·Cancer·F J VriesendorpH M Vriesendorp
Mar 17, 1999·International Journal of Cancer. Journal International Du Cancer·A RosendahlM Dohlsten
Mar 20, 1998·International Journal of Cancer. Journal International Du Cancer·S RiedleM Zöller
Mar 27, 2001·European Journal of Immunology·P thor StratenJ C Becker
Jul 1, 1998·International Reviews of Immunology·E Tartour, W H Fridman
Oct 16, 2019·The Journal of Experimental Medicine·Jonathan G PolGuido Kroemer
Apr 4, 2021·Antibodies·Erin RunbeckSophie Papa

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.